Advances in multi-therapies for the treatment of Ewing's sarcoma

Abstract

Ewing's sarcoma (ES) is a type of bone and soft tissue tumor that is highly invasive and primarily occurs in children and adolescents. In recent years, with the combination chemotherapy, surgery, and radiotherapy, prognosis, and quality of life have significantly improved. The overall survival (OS) rate is 65%–75%. However, metastasis and recurrence after surgical resection are still the main determinants of mortality. The OS rate in these patients is <30%. Exploring the pathogenesis of ES and looking for effective targeted therapies are the primary focus of many research teams. A global effort to improve the clinical efficacy of chemotherapy while reducing the toxic side effects, has led to further advances. We summarize the current multidisciplinary treatment advances in ES, with an emphasis on molecular targeted therapy and immunotherapy.